GlassScriptPhysician profile
Michael J Welch
NPI 1699794222
$3,236.21
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $270 · 2021: $2,207 · 2022: $117.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,680.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $293.06 | 2019-2021 | |
| Pfizer INC. | $256.46 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $251.47 | 2019-2022 | |
| Glaxosmithkline, LLC. | $141.85 | 2019-2021 | |
| Grifols USA, LLC | $117.49 | 2020-2021 | |
| Kaleo, INC. | $115.73 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $109.00 | 2020 | |
| Shire North American Group INC | $78.58 | 2019 | |
| Csl Behring | $67.63 | 2019-2021 | |
| Genzyme Corporation | $53.49 | 2019-2022 | |
| Alk-Abello, INC | $23.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.36 | 2019 | |
| Phadia US INC. | $12.22 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.